Biosimilar vitalizing Korea’s drug industry
Published: 2011-12-22 06:59:00
Updated: 2011-12-22 06:59:00
Biosimilars are widely seen as a new engine of Korea’s economic growth. The drug company that pioneered its production now boasts of the largest market cap not only among pharmaceutical firms but also among the KOSDAQ-listed.
Leading pharmaceutical firms like Dong-A Pharmaceutical, Green Cros...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
